Since the role of both PKD2 and PKD3/PKCν in the pathology of DLBCL is unclear, further investigation is needed to clarify whether the observed regulations contribute to the anti-tumor efficacy of tirabrutinib in TMD8. This evidence concerns the gene PKD2 and diffuse large B-cell lymphoma.